Author:
Kazemifard Setare,Dashti Mahmood
Publisher
Springer International Publishing
Reference16 articles.
1. Yurova KA, Khaziakhmatova OG, Melashchenko ES, Malashchenko VV, Shunkin EO, Shupletsova VV, Ivanov PA, Khlusov IA, Litvinova LS. Cellular and molecular basis of osteoblastic and vascular niches in the processes of hematopoiesis and bone remodeling (a short review of modern views). Curr Pharm Des. 2019;25(6):663–9. https://doi.org/10.2174/1381612825666190329153626.
2. Gruber R. Molecular and cellular basis of bone resorption. Wien Med Wochenschr. 2015;165(3–4):48–53. https://doi.org/10.1007/s10354-014-0310-0. Epub 2014 Sep 16.
3. Huang XL, Huang LY, Cheng YT, Li F, Zhou Q, Wu C, Shi QH, Guan ZZ, Liao J, Hong W, Hong W, et al. Zoledronic acid inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways. Int J Mol Med. 2019;44:582–92.
4. Bar-Shavit Z. The osteoclast: a multinucleated, hematopoietic-origin, bone-resorbing osteoimmune cell. J Cell Biochem. 2007;102(5):1130–9. https://doi.org/10.1002/jcb.21553. PubMed.
5. Lacey DL, Boyle WJ, Simonet WS, et al. Bench to bedside: elucidation of theOPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012;11(5):401–19.